Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women

G. B. Melis, M. Gambacciani, A. M. Paoletti, F. Beneventi, V. Mais, P. Baroldi, P. Fioretti

Research output: Contribution to journalArticle

Abstract

Two different single doses (400 and 600 μg) of the new long-acting dopamine agonist cabergoline (CBG) were given to 12 normal cycling women, 17 puerperal women, and 24 hyperprolactinemic women (12 with idiopathic hyperprolactinemia and 12 with pituitary adenoma). Plasma PRL was determined in blood samples collected before and at frequent intervals for 5 days after CBG administration. Both CBG doses induced marked inhibition of PRL secretion in all women. A decrease in plasma PRL levels was evident 1-2 h after CBG administration and persisted for up to 5 days. The 600-μg CBG dose had a more potent (P <0.05) PRL inhibitory effect than the 400-μg dose in normal, puerperal, and hyperprolactinemic women. Moreover, while 400 μg CBG prevented lactation in 3 of 7 puerperal women, 600 μg CBG prevented lactation in 5 of 5 puerperal women. A moderate blood pressure decrease occurred 3-6 h after CBG treatment, but no other side-effects occurred. These results demonstrate that CBG induces a dose-related inhibition of PRL secretion in normal women as well as in puerperal and hyperprolactinemic women. The potent long-lasting PRL inhibitory effect of CBG in conjunction with the absence of side-effects typical of dopaminergic compounds suggest that this drug is an advance in the medical treatment of hyperprolactinemia.

Original languageEnglish
Pages (from-to)541-545
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume65
Issue number3
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women'. Together they form a unique fingerprint.

  • Cite this